PFE - Beam Therapeutics: Slow Developmental Progress But Promising Potential
2024-07-01 14:34:13 ET
Summary
- Beam Therapeutics Inc. is a gene editing company focused on precision genetic medicines through base editing.
- The company has notable collaborations with Pfizer and other pharma concerns, with several pipeline milestones in 2024.
- The company is making slow developmental progress, but has some significant longer-term potential and a cash-rich balance sheet for now.
- An updated analysis around Beam Therapeutics follows in the paragraphs below.
Our last look at Beam Therapeutics Inc. ( BEAM ) occurred in February 2023. We concluded that article saying the stock at most merit a small "watch item" position for speculative investors. The shares have fallen since then, as they have for most gene editing concerns. This is not that surprising given that most paradigm shifts in biotech (EX, stem cell therapy, CAR-T) also seem to take much longer to develop than initially hoped. Given it has been nearly a year and a half since we peaked in at this developmental firm, it seems a good time to circle back to Beam Therapeutics. An updated analysis follows below....
Beam Therapeutics: Slow Developmental Progress, But Promising Potential